Exhibit 4.1


 


DESCRIPTION
OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934


 


Enochian
Biosciences, Inc., a Delaware corporation (the “Company”) has one class of securities registered under Section
12 of the Securities Exchange Act of 1934, as amended: the Company’s common stock, par value $0.0001 per share (the “Common
Stock”).


 


Description
of Common Stock


 


The
following description of our common stock is based upon our certificate of incorporation, as amended, our bylaws and applicable
provisions of law, in each case as currently in effect. This discussion does not purport to be complete and is qualified in its
entirety by reference to our amended and restated articles of incorporation, as amended, and our bylaws, copies of which are filed
as exhibits to the Annual Report on From 10-K to which this description is an exhibit.


 


Authorized
Shares


 


We
are authorized to issue 100,000,000 shares of Common Stock.


 


Common
Stock


 


Voting
-- Each outstanding share of Common Stock is entitled to one vote on all matters submitted to a vote of stockholders.
There are no cumulative voting rights.


 


Dividends
-- Each stockholder is entitled to receive the dividends as may be declared by our board of directors out of funds legally
available for dividends. . Our board of directors is not obligated to declare a dividend. Any future dividends will be subject
to the discretion of our board of directors and will depend upon, among other things, future earnings, the operating and financial
condition of our Company, its capital requirements, general business conditions and other pertinent factors.


 


Liquidation
Rights -- Each stockholder is entitled in the event of liquidation, to share pro rata in any distribution of our assets
after payment of liabilities, subject to the rights and preferences of the holders of any outstanding shares of any series of
our preferred stock.


 


Other
Matters -- Holders of our common stock have no conversion, preemptive or other subscription rights, and there are no redemption
rights or sinking fund provisions with respect to the common stock. All of the issued and outstanding shares of common stock on
the date of this report are validly issued, fully paid and non-assessable.


    


Transfer
Agent


 


The
transfer agent of our Common Stock offered hereby is Action Stock Transfer, 2469 E. Fort Union Boulevard, Suite 214, Salt Lake
City, Utah 84121. Its telephone number is (801) 274-1088.


 


Anti-Takeover
Effects of Certain Provisions of Delaware Law and Our Charter Documents


 


The
following is a summary of certain provisions of Delaware law, our Certificate of Incorporation and our bylaws. This summary does
not purport to be complete and is qualified in its entirety by reference to the corporate law of Delaware and our Certificate
of Incorporation and bylaws.


 






     


    


    

 


Effect
of Delaware Anti-Takeover Statute. We are subject to Section 203 of the Delaware General Corporation Law, an anti-takeover
law. In general, Section 203 prohibits a Delaware corporation from engaging in any business combination (as defined below) with
any interested stockholder (as defined below) for a period of three years following the date that the stockholder became an interested
stockholder, unless:


 


	 	●	prior
    to that date, the board of directors of the corporation approved either the business combination or the transaction that resulted
    in the stockholder becoming an interested stockholder;


 


	 	●	upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares of voting stock outstanding (but not the voting stock owned by the interested stockholder) those shares owned by persons who are directors and officers and by excluding employee stock plans in which employee participants do not have the right to determine whether shares held subject to the plan will be tendered in a tender or exchange offer; or

                                                                                 

	 	●	on
    or subsequent to that date, the business combination is approved by the board of directors of the corporation and authorized
    at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of
    the outstanding voting stock that is not owned by the interested stockholder.


 


Section
203 defines “business combination” to include the following:


 


	 	●	any
    merger or consolidation involving the corporation and the interested stockholder;


 


	 	●	any
    sale, transfer, pledge or other disposition of 10% or more of the assets of the corporation involving the interested stockholder;


 


	 	●	subject
    to certain exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation
    to the interested stockholder;


 


	 	●	subject
    to limited exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share
    of the stock of any class or series of the corporation beneficially owned by the interested stockholder; or


 


	 	●	the
    receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits
    provided by or through the corporation.


 


In
general, Section 203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding
voting stock of the corporation, or who beneficially owns 15% or more of the outstanding voting stock of the corporation at any
time within a three-year period immediately prior to the date of determining whether such person is an interested stockholder,
and any entity or person affiliated with or controlling or controlled by any of these entities or persons.


 


Our
Charter Documents. Our charter documents include provisions that may have the effect of discouraging, delaying or preventing
a change in control or an unsolicited acquisition proposal that a stockholder might consider favorable, including a proposal that
might result in the payment of a premium over the market price for the shares held by our stockholders. Certain of these provisions
are summarized in the following paragraphs.


 


Effects
of authorized but unissued common and preferred stock. One of the effects of the existence of authorized but unissued common
and preferred stock may be to enable our board of directors to make more difficult or to discourage an attempt to obtain control
of our Company by means of a merger, tender offer, proxy contest or otherwise, and thereby to protect the continuity of management.
If, in the due exercise of its fiduciary obligations, the board of directors were to determine that a takeover proposal was not
in our best interest, such shares could be issued by the board of directors without stockholder approval in one or more transactions
that might prevent or render more difficult or costly the completion of the takeover transaction by diluting the voting or other
rights of the proposed acquirer or insurgent stockholder group, by putting a substantial voting block in institutional or other
hands that might undertake to support the position of the incumbent board of directors, by effecting an acquisition that might
complicate or preclude the takeover, or otherwise.


 


Cumulative
Voting. Our Certificate of Incorporation does not provide for cumulative voting in the election of directors, which would
allow holders of less than a majority of the stock to elect some directors.


 


Vacancies.
Our Certificate of Incorporation provides that all vacancies may be filled by the affirmative vote of a majority of directors
then in office, even if less than a quorum.